載入...
Proteasome inhibition enhances antitumour effects of gemcitabine in experimental pancreatic cancer
BACKGROUND: The clinical benefit of gemcitabine, the standard systemic therapy of pancreatic cancer (PaCa), remains modest as a result of high chemoresistance. The proteasome inhibitor bortezomib has antitumour activity against PaCa in vitro and in vivo. We examined the antitumour activity of combin...
Na minha lista:
| Main Authors: | , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Blackwell Publishing Ltd
2009
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2785956/ https://ncbi.nlm.nih.gov/pubmed/20495713 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1477-2574.2009.00109.x |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|